Citalopram for agitation in Alzheimer’s disease (CitAD): design and methods

BACKGROUND: Agitation is one of the most common neuropsychiatric symptoms of Alzheimer’s disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limited. The citalopram for agitation in Alzheimer’s disease...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Drye, Lea T., Ismail, Zahinoor, Porsteinsson, Anton P., Rosenberg, Paul B., Weintraub, Daniel, Marano, Christopher, Pelton, Gregory, Frangakis, Constantine, Rabins, Peter V., Munro, Cynthia A., Meinert, Curtis L., Devanand, D.P., Yesavage, Jerome, Mintzer, Jacobo E., Schneider, Lon S., Pollock, Bruce G., Lyketsos, Constantine G.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3333484/
https://ncbi.nlm.nih.gov/pubmed/22301195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2011.01.007
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items